U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

             FORM 10-Q.--QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2002

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

For the transition period from ___________________ to _______________________

Commission file number:  000-25549

                                 INTERDENT, INC.
           (Exact name of registrant as specified in its charter)

      Delaware                                  95-4710504
(State or other jurisdiction         (I.R.S. Employer Identification No.)
of incorporation or organization)

        222 No. Sepulveda Blvd., Suite 740, El Segundo, CA 90245-4340
                  (Address of principal executive offices)

                           (310) 765-2400
          (Registrant's telephone number, including area code)

                                    No Change

   (Former name, former address and former fiscal year, if changed since last
                                       report)


Indicate by check mark whether the registrant (1) filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                             Yes     X     No


As of July 17, 2002, 4,019,586 shares of the issuer's common stock were
outstanding.






<PAGE>



PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements
                                 INTERDENT, INC.
                                AND SUBSIDIARIES
                      Condensed Consolidated Balance Sheets
                  (Unaudited, in thousands, except share amounts)
<TABLE>
<CAPTION>

------------------------------------------------------------------------------------------------------------------------------------

                                                                                                  June 30,           December 31,
                                         Assets                                                     2002                 2001
                                                                                              ------------------   -----------------
<S>                                                                                       <C>                   <C>
Current assets:
    Cash and cash equivalents                                                              $             5,608  $             7,189
    Accounts receivable, net                                                                            18,246               20,092
    Management fees receivable                                                                             602                  581
    Supplies inventory                                                                                   3,810                3,613
    Prepaid and other current assets                                                                     4,531                4,051
                                                                                              ------------------   -----------------
           Total current assets                                                                         32,797               35,526
                                                                                              ------------------   -----------------

Property and equipment, net                                                                             19,260               20,945
Intangible assets, net                                                                                 148,074              147,532
Other assets                                                                                             9,313                3,021
                                                                                              ------------------   -----------------
           Total assets                                                                    $           209,444  $           207,024
                                                                                              ==================   =================

              Liabilities, Redeemable Common Stock and Shareholders' Equity

Current liabilities:
    Accounts payable                                                                       $             5,483  $             7,996
    Accrued payroll and payroll related costs                                                           10,427                9,022
    Other current liabilities                                                                           15,619               11,187
    Current portion of long-term debt and capital lease obligations                                     19,327               13,666
                                                                                              ------------------   -----------------
           Total current liabilities                                                                    50,856               41,871
                                                                                              ------------------   -----------------

Long-term liabilities:
    Obligations under capital leases, net of current portion                                               755                1,251
    Long-term debt, net of current portion                                                             116,648              119,738
    Convertible senior subordinated debt                                                                36,642               35,058
    Other long-term liabilities                                                                          1,621                1,871
                                                                                              ------------------   -----------------

           Total long-term liabilities                                                                 155,666              157,918
                                                                                              ------------------   -----------------

           Total liabilities                                                                           206,522              199,789
                                                                                              ------------------   -----------------

Redeemable common stock, $0.001 par value, 17,286 and 17,905 shares issued and
  outstanding in 2002 and 2001, respectively                                                               997                1,047
                                                                                              ------------------   -----------------

Shareholders' equity:
    Preferred stock, $0.001 par value, 30,000,000 shares authorized:
       Preferred stock - Series A, 100 shares authorized and outstanding                                     1                    1
       Convertible Preferred stock - Series B, 70,000 shares authorized, zero shares
      issued and outstanding                                                                                --                   --
       Preferred stock - Series C, 100 shares authorized, zero shares issued and
      outstanding                                                                                           --                   --
       Convertible Preferred stock - Series D, 2,000,000 shares authorized, 1,574,608
      and 1,628,663 shares issued and outstanding in 2002 and 2001                                      11,688               12,089
    Common stock, $0.001 par value, 50,000,000 shares authorized, 4,002,300 and
      3,976,551 shares issued and outstanding in 2002 and 2001, respectively                                 4                    4
     Additional paid-in capital                                                                         76,907               76,502
    Shareholder note receivable                                                                           (199)                (184)
    Accumulated deficit                                                                                (86,476)             (82,224)
                                                                                              ------------------   -----------------
           Total shareholders' equity                                                                    1,925                6,188
                                                                                              ------------------   -----------------
           Total liabilities, redeemable common stock and shareholders' equity             $           209,444  $           207,024
                                                                                              ==================   =================

</TABLE>

See accompanying notes to condensed consolidated financial statements.

<PAGE>


                                 InTERDENT, INC.
                                and subsidiaries

                 Condensed Consolidated Statements of Operations

                (Unaudited, in thousands, except per share amounts)
<TABLE>
<CAPTION>

----------------------------------------------------------------------------------------------------------------------------------
                                                                                  Three Months Ended          Six Months Ended
                                                                                        June 30,                   June 30,
                                                                                   2002         2001         2002          2001
                                                                                -----------   ----------   ----------   -----------
<S>                                                                            <C>          <C>           <C>          <C>
Dental practice net patient service revenue                                    $    64,134   $   68,036   $  127,495   $   139,862
Net management fees                                                                    191        8,021          388        19,554
Licensing and other fees                                                               196          186          363           405
                                                                                -----------   ----------   ----------   -----------

           Total revenues                                                           64,521       76,243      128,246       159,821
                                                                                -----------   ----------   ----------   -----------
Operating expenses:
    Clinical salaries, benefits, and provider costs                                 31,010       34,254       61,966        69,793
    Practice non-clinical salaries and benefits                                      8,310       10,729       16,806        22,449
    Dental supplies and lab expenses                                                 6,565        9,391       13,832        20,310
    Practice occupancy expenses                                                      3,364        4,531        6,673         9,492
    Practice selling, general and administrative expenses                            5,963        6,819       10,764        14,920
    Corporate selling, general and administrative expenses                           3,071        3,518        7,308         6,741
    Stock compensation expense                                                          74          853          147         1,744
    (Gain) loss on dental location dispositions and impairment
      of              long-lived assets                                              (192)        5,934        (192)         5,934
    Depreciation and amortization                                                    1,027        3,208        2,036         6,423
                                                                                -----------   ----------   ----------   -----------
           Total operating expenses                                                 59,192       79,237      119,340       157,806
                                                                                -----------   ----------   ----------   -----------
           Operating income (loss)                                                   5,329      (2,994)        8,906         2,015
                                                                                -----------   ----------   ----------   -----------
Nonoperating expense:
    Interest expense, net                                                          (5,783)      (5,192)     (10,237)      (10,679)
    Debt and equity financing costs                                                     --      (3,886)           --       (3,886)
    Other, net                                                                        (97)         (54)        (257)          (46)
                                                                                -----------   ----------   ----------   -----------
                 Nonoperating expense, net                                         (5,880)      (9,132)     (10,494)      (14,611)
                                                                                -----------   ----------   ----------   -----------
           Loss before income taxes                                                  (551)     (12,126)      (1,588)      (12,596)

Provision for income taxes                                                              30           50           60           100
                                                                                -----------   ----------   ----------   -----------
           Loss before extraordinary item                                            (581)     (12,176)      (1,648)      (12,696)

 Extraordinary loss on debt extinguishments                                        (2,604)      (5,601)      (2,604)       (5,601)
                                                                                -----------   ----------   ----------   -----------
           Net loss                                                                (3,185)     (17,777)      (4,252)      (18,297)
Accretion of redeemable common stock                                                    --           --           --           (1)
                                                                                -----------   ----------   ----------   -----------
           Net loss attributable to common stock                               $   (3,185)   $ (17,777)   $  (4,252)   $  (18,298)
                                                                                ===========   ==========   ==========   ===========
Loss per share attributable to common stock - basic and dilutive               $    (0.83)   $   (4.61)   $   (1.11)   $    (4.70)
                                                                                ===========   ==========   ==========   ===========
</TABLE>

See accompanying notes to condensed consolidated financial statements.


<PAGE>



                                 INTERDENT, INC.
                                and subsidiaries

                 Condensed Consolidated Statements of Cash Flows

                            (Unaudited, in thousands)
<TABLE>
<CAPTION>

-----------------------------------------------------------------------------------------------------------------------------------

                                                                                                   Six Months Ended June 30,
                                                                                                    2002               2001
                                                                                              -----------------  ------------------
<S>                                                                                         <C>                  <C>
Cash flows from operating activities:
    Net loss                                                                                $           (4,252)$          (18,297)
    Adjustments to reconcile net loss to net cash provided by operating activities:
      Depreciation and amortization                                                                      2,036              6,423
      (Gain) loss on dental location dispositions and impairment of long-lived assets                     (192)             5,934
      Loss on disposal of assets                                                                           402                107
      Non-employee stock options granted and stock issued for fees and compensation                         --                  2
      Amortization of stock compensation expense                                                            --              1,478
      Interest income on shareholder notes                                                                 (15)                (6)
      Notes and warrants issued or accrued for debt amendment fees, interest
        payment-in-kind and accrued interest                                                             6,339              6,016
      Interest amortization on deferred financing costs and discounted debt                              1,903              7,475
      Change in assets and liabilities, net of the effect of acquisitions:
       Accounts receivable, net                                                                          1,840                 42
       Management fees receivable                                                                          (21)              (395)
       Supplies inventory                                                                                 (199)                10
       Prepaid expenses and other current assets                                                           302              1,531
       Other assets                                                                                       (182)              (428)
       Accounts payable                                                                                 (2,513)             3,136
       Accrued payroll and payroll related costs                                                           523                251
       Accrued merger and restructure                                                                     (156)              (207)
        Other liabilities                                                                                1,429               (380)
                                                                                              -----------------  ------------------
                Net cash provided by operating activities                                                7,244             12,692
                                                                                              -----------------  ------------------
Cash flows from investing activities:
    Purchase of property and equipment                                                                    (802)            (2,087)
    Proceeds from sale of property and equipment                                                            --                 33
    Net payments received on notes receivable from professional associations                                --                103
    Net advances to professional associations                                                               --             (3,163)
    Proceeds from disposition of dental locations                                                          600             22,141
    Cash paid for acquisitions and earn-outs, including direct costs, net of cash                       (1,242)            (3,580)
      acquired
                                                                                              -----------------  ------------------
                Net cash (used in) provided by investing activities                                     (1,444)            13,447
                                                                                              -----------------  ------------------
Cash flows from financing activities:
    Net payments on credit facility                                                                     (2,397)           (22,804)
    Payments on long-term debt and obligations under capital leases                                     (3,669)            (2,819)
    Payments of deferred financing costs                                                                (1,294)            (2,301)
    Proceeds from issuance of common and preferred stock                                                     4                 --
    Exercise of put rights                                                                                 (25)              (376)
                                                                                              -----------------  ------------------
                Net cash used in financing activities                                                   (7,381)           (28,300)
                                                                                              -----------------  ------------------
                Decrease in cash and cash equivalents                                                   (1,581)            (2,161)
Cash and cash equivalents, beginning of period                                                           7,189              5,293
                                                                                              -----------------  ------------------
Cash and cash equivalents, end of period                                                    $            5,608 $            3,132
                                                                                              =================  ==================
Cash paid for interest                                                                      $            4,023 $            6,660
                                                                                              =================  ==================
Cash (refunded) paid for income taxes                                                       $               -- $           (1,437)
                                                                                              =================  ==================

</TABLE>


See accompanying notes to condensed consolidated financial statements.


<PAGE>



                                 INTERDENT, INC.
                                and subsidiaries

                             June 30, 2002 and 2001

              Notes to Condensed Consolidated Financial Statements

         (Unaudited, in thousands, except per share and share amounts)

(1) ORGANIZATION


Headquartered in El Segundo, California, InterDent, Inc. ("InterDent" or the
"Company") was incorporated on October 13, 1998 as a Delaware corporation to
facilitate the business combination of Gentle Dental Service Corporation
("GDSC") and Dental Care Alliance ("DCA") that occurred in March 1999. Prior to
the combination, GDSC and DCA were each publicly traded dental practice
management companies since 1997.

The Company is a provider of dental practice management services to
multi-specialty dental professional corporations and associations ("PAs") in the
United States. The Company provides management services to affiliated PAs under
long-term management service agreements ("MSAs"). Under the MSAs, the Company
bills and collects patient receivables and provides administrative and
management support services. Each PA is responsible for employing and directing
the professional dental staff and providing all clinical services to the
patients. The dentists employed through the Company's network of affiliated
dental associations provide patients with affordable, comprehensive dentistry
services, which include general dentistry, endodontics, oral pathology, oral
surgery, orthodontics, pedodontics, periodontics and prosthodontics.

Through May 31, 2001, the Company provided management services to dental
practices in selected markets in Arizona, California, Florida, Georgia, Hawaii,
Idaho, Indiana, Kansas, Maryland, Michigan, Nevada, Oklahoma, Oregon,
Pennsylvania, Virginia and Washington. Effective May 31, 2001, the Company
completed the stock sale of Dental Care Alliance, Inc. ("DCA"), a wholly-owned
subsidiary, and certain other assets in Maryland, Virginia, and Indiana, for
$36.0 million less the assumption of certain debt and operating liabilities. The
net sales proceeds were utilized to pay down existing borrowings under the
credit facility. Also, the Company has retained an option to repurchase the
division at a future date and entered into an ongoing collaboration agreement
and license agreement to provide the Company's proprietary software.

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company provides management services to the PAs under long-term MSAs that
generally have an initial term of 40 years. Under the provisions of the MSAs,
the Company owns the non-professional assets at the affiliated practice
locations, including equipment and instruments, bills and collects patient
receivables, and provides all administrative and management support services to
the PAs. These administrative and management support services include:
financial, accounting, training, efficiency and productivity enhancement,
recruiting, marketing, advertising, purchasing, and related support personnel.
The PAs employ the dentists and the hygienists while the Company employs or
co-employs all administrative personnel.

The Emerging Issues Task Force ("EITF") of the Financial Accounting Standards
Board reached a consensus on the accounting for transactions between physician
practice management companies and physician practices and the financial
reporting of such entities (EITF issue number 97-2). For financial reporting
purposes, EITF 97-2 mandates the consolidation of physician practice activities
with the practice management company when certain conditions have been met, even
though the practice management company does not have a direct equity investment
in the physician practice. The accompanying condensed consolidated financial
statements are prepared in conformity with the consensus reached in EITF 97-2.

Simultaneous to the execution of an MSA with each PA, the Company also entered
into a shares acquisition agreement ("SAA"). Subsequent to the sale of DCA,
under all of the SAAs entered into except for one, the Company has the right to
designate the purchaser (successor dentist) to purchase from the PA shareholders
all the shares of the PA for a nominal price of a thousand dollars or less.
Under these SAAs, the Company has the unilateral right to establish or effect a
change in the PA shareholder, at will, and without consent of the PA
shareholder, on an unlimited basis. Under EITF 97-2, the agreements with the PA
shareholders qualify as a friendly doctor arrangement. Consequently, under EITF
97-2, the Company consolidates all the accounts of those PAs in the accompanying
condensed consolidated financial statements. Accordingly, the condensed
consolidated statements of operations include the net patient service revenues
and related expenses of these PAs and all significant intercompany transactions
have been eliminated.

Each of the DCA SAAs entered into with the PAs did not have the nominal price
provision. Also, subsequent to the DCA sale one remaining SAA entered into with
a PA does not have the nominal price provision. Rather, the SAA purchase price
is based upon a multiple of earnings, as defined. As a result, the agreements do
not meet the criteria of consolidation under EITF 97-2 and the condensed
consolidated statements of operations exclude the net patient service revenues
and expenses of these PAs. Rather, the condensed consolidated statements of
operations include only the Company's net management fee revenues generated and
expenses associated with providing services under the MSAs.

Liquidity

The Company experienced losses attributed to common stock of $4,252 during the
six months ended June 30, 2002 and for fiscal years 2001 and 2000, $35,080 and
$48,712, respectively. These past significant losses included certain charges
for asset impairments, disposition of DCA and certain other dental locations,
and debt restructuring and debt extinguishments, which the Company believes are
unusual in nature. Although the Company has experienced significant losses over
the last two years due to these unusual charges, the Company's dental facilities
continue to generate significant positive cash, as reflected in cash flows from
operations of $7,244 for the six months ended June 30, 2002 and for fiscal years
2001 and 2000, $19,379 and $9,545, respectively.

During 2001 the Company hired an advisor to review the Company's operations to
determine whether improvements could be made, which could be implemented in the
near and long term. The advisor, along with Company personnel, reviewed such
strategies as revenue enhancements, modifications to managed care contracts,
savings from procurement efficiencies, and reduction of headcount at dental
office and corporate locations. As a result of this review, a number of
initiatives to improve operations were implemented in late 2001 and early 2002.
These initiatives are projected to increase cash flow in 2002 and in future
periods through the Company's emphasis on increasing same store revenues and
curtailing direct operating costs. Through June 30, 2002, the Company has met
its earning projections.

These initiatives and the projected improvements in operations and cash flows
played a vital role in the Company's ability to negotiate modifications to its
credit agreement that was consummated on April 15, 2002, as more fully described
in Note 5. These modifications resulted in a permanent waiver of past covenant
violations, and reset the covenants to levels, which the Company's projections
indicate will be met through March 31, 2003. The Company also incurred certain
fees and expenses, and the interest rate was increased by 1.0%. In addition, the
principal amortization schedule was significantly modified such that
approximately $20,700 of payments due through March 31, 2003 were deferred until
the second quarter 2003, and only $7,907 of principal payments are due through
June 30, 2003. The Company paid the $2,397 scheduled installment due April 1,
2002.

The Company believes that it will be able to make all scheduled debt payments
through March 31, 2003, and those due under its earn-out agreements, along with
meeting its other obligations. Further, the Company has significant debt due
beginning April 1, 2003, which must be refinanced, modified, or otherwise
retired with the proceeds of other financing or capital transactions. There can
be no assurance that the Company will meet its obligations through March 31,
2003, and that any such financing will be available or available on terms
acceptable to the Company.

Interim reporting

The accompanying unaudited interim condensed consolidated financial statements
of InterDent have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission ("SEC"). Certain information and note
disclosures normally included in annual consolidated financial statements have
been condensed or omitted as permitted under those rules and regulations. We
believe all adjustments, consisting only of normal, recurring adjustments
considered necessary for a fair presentation, have been included and that the
disclosures made are adequate to insure that the information presented is not
misleading. To obtain a more detailed understanding of Company results, it is
suggested that these financial statements be read in conjunction with the
consolidated financial statements and related notes for the year ended December
31, 2001 included in Form 10-K filed on April 16, 2002. The results of
operations for the three and six months ended June 30, 2002 are not necessarily
indicative of the results of operations for the entire year.



<PAGE>



Net revenues

Revenues consist primarily of PA net patient service revenue ("net patient
revenue") and Company net management fees. Net patient revenue represents the
consolidated revenue of the PAs reported at the estimated net realizable amounts
from patients, third party payors and others for services rendered, net of
contractual adjustments. Net management fees represent amounts charged to the
unconsolidated PAs in accordance with the MSA as a percentage of the PAs net
patient service revenue under MSAs, net of provisions for contractual
adjustments and doubtful accounts. Such revenues are recognized as services are
performed based upon usual and customary rates or contractual rates agreed to
with managed care payors.

Net patient revenues include amounts received under capitated managed care
contracts from certain wholly-owned subsidiaries that are subject to regulatory
review and oversight by various state agencies. The subsidiaries are required to
file statutory financial statements with the state agencies and maintain minimum
tangible net equity balances and restricted deposits. The Company is in
compliance with such requirements as of June 30, 2002. Total revenues subject to
regulatory review and oversight by various state agencies were $24,897 and
$23,407 for the six months ended June 30, 2002 and 2001, respectively.

Accounts receivable

Accounts receivable principally represent receivables from patients and
insurance carriers for dental services provided by the related PAs at
established billing rates, less allowances and discounts for patients covered by
third party payor contracts. Payments under these programs are primarily based
on predetermined rates. In addition, a provision for doubtful accounts is
provided based upon expected collections and is included in practice selling,
general and administrative expenses. These contractual allowances, discounts and
allowance for doubtful accounts are deducted from accounts receivable in the
accompanying condensed consolidated balance sheets. The discounts and allowances
are determined based upon historical realization rates, the current economic
environment and the age of accounts. Changes in estimated collection rates are
recorded as a change in estimate in the period the change is made.

Intangible assets

Intangible assets result primarily from the excess of cost over the fair value
of net tangible assets purchased. Such intangibles primarily relate to MSAs and
goodwill associated with dental practice acquisitions. Intangibles relating to
MSAs consist of the costs of purchasing the rights to provide management support
services to PAs over the initial noncancelable terms of the related agreements,
usually 25 to 40 years. The MSAs can be perpetually extended by virtue of the
SAAs entered into by the Company with each PA. Under these agreements, the PAs
have agreed to provide dental services on an exclusive basis only through
facilities provided by the Company, which is the exclusive administrator of all
non-dental aspects of the acquired PAs, providing facilities, equipment, support
staffing, management and other ancillary services. The agreements are
noncancelable except for performance defaults. Through December 31, 2001, the
Company's intangible assets were amortized on the straight-line method, ranging
from 5 years for service mark to 25 years for MSAs and goodwill.

In July 2001, the FASB issued Statement of Financial Accounting Standard No.
142, "Goodwill and Other Intangible Assets" ("SFAS 142"), which became effective
January 1, 2002. Under SFAS 142, goodwill and indefinite lived assets are no
longer amortized but are reviewed annually for impairment. As a result, the
Company's service mark, MSAs and goodwill intangible assets are no longer being
amortized. The tests for measuring impairment under SFAS 142 are more stringent
than previous tests required by Statement of Financial Accounting Standard No.
121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived
Assets to be Disposed of." The Company is currently performing the required
impairment tests of goodwill and indefinite lived intangible assets as of
January 1, 2002. The Company has completed the first step of the two-step
transitional impairment analysis required by SFAS 142. This analysis indicated
that the carrying amount of the net assets of the Company exceeds the fair
value. Preliminary results of the second step of the transitional impairment
analysis indicates that an impairment charge totaling $50,000 to $100,000 will
be required, although such analysis in not complete. The Company expects to
complete this analysis in the fourth quarter of 2002.



<PAGE>



During 2002, the Company did not record amortization on its intangible assets as
all such assets are determined to have indefinite lives. The following table
reflects comparable pro forma results of operations for the three and six months
ended June 30, 2002 and 2001 as though the adoption of the non-amortization
provisions of SFAS 142 occurred as of January 1, 2001:
<TABLE>
<CAPTION>

                                                                          Three Months Ended          Six Months Ended
                                                                               June 30,                   June 30,
                                                                          2002          2001          2002         2001
                                                                       ------------  ------------  -----------  -----------
<S>                                                                  <C>            <C>           <C>          <C>
Net loss attributed to common stock:
  As reported                                                        $      (3,185)$   (17,777)  $    (4,252) $  (18,298)
  Amortization of indefinite lived intangible assets                            --       1,786            --       3,426
                                                                       ------------  ------------  -----------  -----------
  Pro forma                                                          $      (3,185)$   (15,991)  $    (4,252) $  (14,872)
                                                                       ============  ============  ===========  ===========

  Net loss per share attributable to common stock - basic and
  diluted
  As reported                                                        $      (0.83) $      (4.61) $     (1.11) $     (4.70)
  Pro forma                                                          $      (0.83) $      (4.15) $     (1.11) $     (3.82)
</TABLE>


Long-lived assets

The Company reviews its long-lived assets for impairment when events or changes
in circumstances indicate that the carrying amount of assets may not be
recoverable. To perform that review, the Company estimates the sum of expected
future undiscounted net cash flows from assets. If the estimated net cash flows
are less than the carrying amount of the asset, the Company recognizes an
impairment loss in an amount necessary to write-down the assets to their fair
value as determined from expected future discounted cash flows. No impairment of
long-lived assets was recorded during the three and six months ended June 30,
2002 and 2001.

Deferred compensation

The Company made advances of $11,500 to certain officers of the Company and
provided certain other officers with a minimum guarantee of the value of their
stock options in order to retain and provide incentives to such officers. In
connection with the advances, such officers issued interest-bearing notes
payable to the Company. Shares of the Company's common stock and options owned
by such officers have been pledged to secure the notes. The notes were included
in shareholders' equity as a reduction to equity. Interest on the notes accrues
at rates ranging from 6.4% to 10.2%. The notes and accrued interest are due June
2004, payable in cash or Company common stock and options with varying minimum
values. The notes and accrued interest were with recourse to the officers until
May or June of 2002, depending upon the individual note agreement, after which
the notes and accumulated interest became non-recourse, subject only to the
underlying pledged collateral.

The difference in the amount of the notes and the value of the collateral at the
date of the loans was being amortized over the life of the notes, representing
stock compensation expense. The amortization reflected the deficit of the
underlying pledged collateral on the individual note dates. The Company also
adjusted the amortization to reflect changes in the quoted fair market value.
The decline, if any, was amortized as stock compensation expense over the life
of the notes. The amortization expense was adjusted cumulatively for changes in
fair value of the collateral. Increases in the stock price, if any, resulted in
a credit to expense, up to the amount of prior expense recognized for this
portion of the notes. In addition, the minimum guarantee of the value of the
stock options was being amortized as stock compensation expense.

The total advance included loans to certain DCA officers. The non-amortized
balance of the advances to DCA officers of $4,600 was sold in connection with
the sale of DCA. Also, during the third quarter of 2001, the entire
non-amortized balance of the remaining notes was written off as a result of the
acceleration of the non-recourse provision of the note due from the former CEO
and the significant decline in the underlying value of the pledged collateral,
which is considered to be other than temporary.

Also, in connection with the execution of an officer's amended employment
agreement, a note receivable and related accrued interest of $182 were to be
forgiven, subject to provisions of the agreement. The note and accrued interest
were being expensed over the twenty-four month service period ending May 2002.
During the third quarter of 2001, the remaining balance on the note was written
off as compensation expense since the note was converted to non-recourse
pursuant to the severance agreement with the officer.

Net loss per share

The Company has adopted Statement of Financial Accounting Standards No. 128,
"Earnings Per Share" ("SFAS 128"). In accordance with SFAS 128, the Company
presents "basic" earnings per share, which is net income or loss divided by the
average weighted common shares outstanding during the period, and "diluted"
earnings per share, which considers the impact of common share equivalents.
Dilutive potential common shares represent shares issuable using the treasury
stock method.

For the six months ended June 30, 2002, and 2001, dilutive potential common
shares of approximately 2,250,000 and 2,850,000, respectively, consisting of
convertible subordinated debt, convertible preferred stock, and the exercise of
certain options and warrants have been excluded from the computation of diluted
income per share as their effect is anti-dilutive.

The following table summarizes the computation of net loss per share:

<TABLE>
<CAPTION>

                                                                   Three Months Ended               Six Months Ended
                                                                        June 30,                        June 30,
                                                                  2002           2001             2002            2001
                                                              -------------  --------------   --------------  -------------
<S>                                                        <C>             <C>              <C>            <C>
Loss before extraordinary item                              $         (581)$      (12,176)  $       (1,648) $     (12,696)
Extraordinary loss on debt extinguishments                          (2,604)        (5,601)          (2,604)        (5,601)
Accretion of redeemable common stock                                    --             --               --             (1)
                                                              -------------  --------------   --------------  -------------
       Net loss attributable to common stock                $       (3,185)       (17,777)          (4,252)       (18,298)
                                                              =============  ==============   ==============  =============

Outstanding Shares Reconciliation:
  Weighted average common shares outstanding                     3,848,655      3,888,153        3,841,060      3,943,242
  Contingent returnable common shares                                   --        (32,674)              --        (51,439)
                                                              -------------  --------------   --------------  -------------
       Outstanding basic and diluted shares                      3,848,655      3,855,479        3,841,060      3,891,803
                                                              =============  ==============   ==============  =============

 Loss per share - basic and diluted:
  Before extraordinary item                                 $       (0.15) $        (3.16)  $        (0.43) $       (3.26)
  Extraordinary loss on debt extinguishments                        (0.68)          (1.45)           (0.68)         (1.44)
                                                              -------------  --------------   --------------  -------------
  Attributable to common stock                              $       (0.83) $        (4.61)  $        (1.11) $       (4.70)
                                                              =============  ==============   ==============  =============
</TABLE>


Segment reporting

The Company has adopted Statement of Financial Accounting Standards No. 131,
"Disclosures about Segments of an Enterprise and Related Information" ("SFAS
131"). SFAS 131 supersedes SFAS 14, "Financial Reporting for Segments of a
Business Enterprise", replacing the "industry segment" approach with the
"management" approach. The management approach designates the internal reporting
that is used by management for making operating decisions and assessing the
performance as the source of the Company's reportable segments. The adoption of
SFAS 131 did not have an impact for the reporting and display of segment
information as each of the affiliated dental practices is evaluated individually
by the chief operating decision maker and considered to have similar economic
characteristics, as defined in the pronouncement, and therefore are aggregated.

Income taxes

Income taxes are accounted for under the asset and liability method in
accordance with Statement of Financial and Accounting Standards No. 109,
"Accounting for Income Taxes" ("SFAS 109"). Under the asset and liability
approach of SFAS 109, deferred tax assets and liabilities are recognized for the
future tax consequences attributed to differences between the financial
statement carrying amounts of existing assets and liabilities and their
respective tax basis. Income tax expense recorded for the three and six months
ended June 30, 2002 and 2001 represents the Company's estimate of state income
tax payable. The Company has a valuation allowance to offset the entire amount
of federal and state tax benefit of loss carryforwards.

Use of estimates

In preparing the financial statements conforming to Generally Accepted
Accounting Principals ("GAAP"), we have made estimates and assumptions that
affect the following:

o    Reported  amounts of assets and  liabilities  at the date of the  financial
     statements;

o    Disclosure  of  contingent  assets  and  liabilities  at  the  date  of the
     financial statements; and

o    Reported amounts of revenues and expenses during the period.

Actual results could differ from those estimates.

New accounting pronouncements

In July 2001, the FASB issued Statement of Financial Accounting Standard No.
141, "Business Combinations" ("SFAS 141"). SFAS 141 eliminates the
pooling-of-interest method of accounting for business combinations and clarifies
the criteria to recognize intangible assets separately from goodwill. SFAS 141
is effective for any business combination accounted for by the purchase method
that is completed after June 30, 2001. The adoption of SFAS 141 is not expected
to have any impact on the Company's financial position or results of operations.

In July 2001, the FASB issued Statement of Financial Accounting Standard No.
142, "Goodwill and Other Intangible Assets" ("SFAS 142"). Under SFAS 142,
goodwill and indefinite lived assets are no longer amortized but are reviewed
annually for impairment. Separate intangible assets that are not deemed to have
an indefinite life will continue to be amortized over their useful lives. The
amortization provisions of SFAS 142 apply to goodwill and intangible assets
acquired after June 30, 2001. With respect to goodwill and intangible assets
acquired prior to June 30, 2001, the provisions of SFAS 142 are effective upon
its adoption effective beginning fiscal year 2002. The Company is currently
performing the required impairment tests of goodwill and indefinite lived
intangible assets as of January 1, 2002. The Company has completed the first
step of the two-step transitional impairment analysis required by SFAS 142. This
analysis indicated that the carrying amount of the net assets of the Company
exceeds the fair value. Preliminary results of the second step of the
transitional impairment analysis indicates that an impairment charge totaling
$50,000 to $100,000 will be required, although such analysis in not complete.
The Company expects to complete this analysis in the fourth quarter of 2002.

In June 2001, the FASB issued Statement of Financial Accounting Standard No.
143, "Accounting for Asset Retirement Obligations" ("SFAS 143"). SFAS 143
addresses financial accounting and reporting for obligations associated with the
retirement of tangible long-lived assets and the associated asset retirement
costs. It applies to legal obligations associated with the retirement of
long-lived assets that result from the acquisition, construction, and
development and (or) the normal operation of a long-lived asset, except for
certain obligations of lessees. This Statement is effective for financial
statements issued for fiscal years beginning after June 15, 2002. The adoption
of SFAS 143 is not expected to have a significant impact on the Company's
financial position or results of operations.

In August 2001, the FASB issued Statement of Financial Accounting Standard No.
144, "Accounting for the Impairment or Disposal of Long-Lived Assets" ("SFAS
144"). SFAS 144 addresses financial accounting and reporting for the impairment
or disposal of long-lived assets. This Statement supersedes SFAS No. 121,
"Accounting for the Impairment of Long-Lived Assets and for the Long-Lived
Assets to Be Disposed Of," and the accounting and reporting provisions of APB
Opinion No. 30, "Reporting the Results of Operations-Reporting the Effects of
Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently
Occurring Events and Transactions," for the disposal of a segment of a business.
The provisions of this Statement are effective for financial statements issued
for fiscal years beginning after December 15, 2001. The provisions of this
Statement generally are to be applied prospectively. The adoption of SFAS 144 is
not expected to have a significant impact on the Company's financial position or
results of operations.

Reclassifications

Certain reclassifications have been made to the 2001 financial statements to
conform to the 2002 presentation.

(3)      REVENUES

Revenues consist primarily of PA net patient service revenue and Company net
management fees. Net patient service revenue represents the consolidated revenue
of the PAs at normal and customary rates from patients, third party payors and
others for services rendered, net of contractual adjustments. Net management
fees represent amounts charged under MSAs to the unconsolidated PAs on an
agreed-upon percentage of the PAs net patient service revenue, net of provisions
for contractual adjustments and doubtful accounts.

The following represents amounts included in the determination of dental
practice net patient service revenue and net management fees:
<TABLE>
<CAPTION>

                                                                       Three Months Ended             Six Months Ended
                                                                            June 30,                      June 30,
                                                                    2002             2001           2002           2001
                                                                 ------------     ------------    ----------    -----------
<S>                                                          <C>              <C>              <C>            <C>
Dental practice net patient service revenue - all PAs         $      64,514   $       80,140   $     128,183 $     170,593
Dental practice net patient service revenue -
 unconsolidated PAs                                                    (380)         (12,104)           (688)      (30,731)
                                                                 ------------     ------------    ----------    -----------
     Reported practice net patient service revenue            $      64,134   $       68,036   $     127,495 $     139,862
                                                                 ============     ============    ==========    ===========

Dental practice net patient service revenue -
 unconsolidated PAs                                           $         380   $       12,104   $         688 $      30,731
Amounts retained by dentists                                           (189)          (4,083)           (300)      (11,177)
                                                                 ------------     ------------    ----------    -----------
     Net management fees                                      $         191   $        8,021   $         388 $      19,554
                                                                 ============     ============    ==========    ===========
</TABLE>




(4) DENTAL PRACTICE AFFILIATIONS AND DISPOSITIONS

Dental practice affiliations

In connection with certain completed affiliation transactions, the Company has
agreed to pay to the sellers' future consideration. The amount of future
consideration payable under earn-outs is generally computed based upon financial
performance of the affiliated dental practices during certain specified periods.
The Company accrues for earn-out payments with respect to these acquisitions
when such amounts are probable and reasonably estimable. In addition to cash
earn-out payments of $938 during the six months ended June 30, 2002, the Company
also converted $1,067 in earn-out amounts due into long-term notes payable. As
of June 30, 2002, future anticipated earn-out payments of $2,814 are accrued and
included in other current liabilities. For those acquisitions with earn-out
provisions, the Company estimates the total maximum earn-out that could be paid,
including amounts already accrued, is between $5,000 and $6,000 from July 2002
to December 2005, which is expected to be paid in a combination of cash and
notes.

Dental practice dispositions

Effective May 31, 2001, the Company completed the sale of its east coast
division to Mon Acquisition Corp., a group led by Steven Matzkin, DDS, former
president of the Company. The assets in the sale (the "East Coast Assets")
included the stock of Dental Care Alliance, Inc. ("DCA"), a wholly-owned
subsidiary, and assets used in the operation and management of certain dental
practices in Maryland, Virginia and Indiana. The transaction also included the
assets associated with the notes receivable made by officers of DCA as discussed
in note 6. The total consideration was $36,000 less the assumption of related
debt and operating liabilities.

Upon the two-year anniversary of the transaction close, InterDent shall have the
right to repurchase the East Coast Assets, based upon a multiple of earnings and
subject to a minimum price, as defined in the agreement. In connection with the
sale of assets, InterDent entered into a five-year license agreement dated May
16, 2001 and amended on May 31, 2001 effective June 1, 2001 for $2,554, payable
in installments, for its proprietary practice management system, subject to
negotiations for additional term extensions. Such amount has been recorded as
deferred revenues and is being amortized over the life of the agreement. The
parties also entered into the transition services agreement dated as of May 16,
2001 and a business collaboration agreement dated as of April 17, 2001 effective
June 1, 2001 delineating the use of the practice management system, the joint
purchase of supplies, the joint negotiation for managed care contracts, training
systems and other similar operational matters.


In the second half of 2001, the Company disposed of six under performing dental
locations. The Company also disposed of one additional dental location in June
2002.


(5) DEBT

In April 2001, the Company entered into amendments to its existing senior
revolving credit facility (the "Credit Facility") to amend certain covenants. In
connection with the execution of the amendments, the banks waived the defaults
under the Credit Facility that existed at December 31, 2000 due to failure to
meet certain financial ratio covenants and reset all covenants for 2001 and
subsequent years. Additionally, the banks agreed to certain other changes
including a revised term and provisions regarding asset sales and new financing.

As consideration for these modifications, the Company agreed to an amendment fee
of $1,000, which was paid during the three months ended June 30, 2001, and an
additional fee of $1,000 payable at maturity of the term loan if certain
conditions are not met. The additional fee was paid in connection with an
additional amendment to the Credit Facility consummated in April 2002, as
discussed below.

On October 1, 2001, the Credit Facility converted into a term loan, with
required quarterly payments. On April 15, 2002, the Company entered into an
amendment to the existing Credit Facility. In connection with the execution of
the amendment, the bank agreed, among other things, to reset certain covenants
and reduce the required future quarterly principal payments of $7,214, which
began on October 1, 2001. In connection with these modifications, the Company
accrued as note principal the remaining $1,000 due as a result of the amendment
in 2001 as discussed above, which is payable upon maturity. The Company also
agreed to an additional amendment fee of $1,000, with cash of $500 payable at
closing and $250 to accrue as additional principal on July 1, 2002 and October
1, 2002, payable upon final maturity of the Credit Facility on September 30,
2003. The July 1 and October 1, 2002 accrual dates are subject to change, as
outlined in the amendment.

Principal amounts owed under the Credit Facility bear interest at LIBOR plus
7.50% or the prime rate plus 5.75%, at the Company's option. In addition to the
cash interest charges outlined above, the Company is to pay an incremental PIK
interest on the outstanding principal balance of 1.0% from April 15, 2002 though
March 31, 2003, increasing to 2.0% from April 1, 2003 through maturity. The
incremental PIK interest is payable upon maturity. The Company is also to pay a
PIK fee equal to 1.0% of the outstanding principal balance on April 15, 2002,
2.0% on October 1, 2002, and 3.0% on April 1, 2003. PIK fees are payable upon
maturity.

Required principal installments are $2,397, which was paid on April 1, 2002,
$300 due on July 1, 2002, October 1, 2002, January 1, 2003, and payments of
$7,214 on April 1, 2003 and July 1, 2003, with the remaining balance due at
maturity on September 30, 2003. The Credit Facility also has mandatory
prepayment provisions for certain asset sale transactions and excess cash flows,
as defined. These prepayment provisions are applied to future required quarterly
installments. Accordingly, $207 of the $300 due on October 1, 2002 was paid in
July as a result of the disposition of one dental location in June 2002.

The Credit Facility contains several covenants, including but not limited to,
restrictions on the Company's ability to incur indebtedness or repurchase
shares, a prohibition on dividends without prior approval, prohibition on
acquisitions, and fees for excess earnout and debt payments, as defined. There
are also financial covenant requirements relating to compliance with specified
cash flow, liquidity, and leverage ratios. The Company's obligations, including
all subsidiaries in the guarantees, under the Credit Facility are secured by a
security interest in the equipment, fixtures, inventory, receivables, subsidiary
stock, certain debt instruments, accounts and general intangibles of each of
such entities.

The 2002 amendment to the Credit Facility met the criteria of substantial
modification as outlined under the provisions of EITF 96-19. As such, the
amendment met the requirements of an extinguishment of debt. Accordingly, in the
second quarter of 2002 the Company recorded an extraordinary loss of
approximately $2,604. The extraordinary loss represents amendment fees of $2,000
incurred to extinguish the original Credit Facility and $604 for the write-off
of the non-amortized portion of deferred financing costs associated with the
original note agreement. Professional fees and bank PIK fees paid, or
anticipated to be paid, of $5,902 for the execution of the amended Credit
Facility have been capitalized and are being amortized over the remaining life
of the Credit Facility. At June 30, 2002 $4,428 in anticipated future PIK fees
are included in other current liabilities.

In June 2000, the Company raised $36,500 from the sale of debt and equity to
Levine Leichtman Capital Partners II, L.P. ("Levine") under a securities
purchase agreement (the "Securities Purchase Agreement"). The equity portion of
the transaction comprised 458,333 shares of common stock valued at $11,000. The
debt portion of the transaction comprised a senior subordinated note with a face
value of $25,500 (the "Levine Note"). As part of the transaction with Levine,
the Company also issued a warrant to purchase 354,167 shares of the Company's
common.

In April 2001, the Company entered into an amendment to the Levine Note that met
the criteria of substantial modification as outlined in EITF 96-19. As such, the
Levine Note was considered extinguished, with a new note issued in its place. In
connection with the amendment, the lender waived the defaults under the Levine
Note that existed at December 31, 2000 due to failure to meet certain financial
ratio covenants and reset all covenants for 2001 and subsequent years, in
addition to certain other modifications. As consideration for the amendment, the
Company paid an amendment fee of $2,250, payable in additional notes, increased
the payment-in-kind ("PIK") interest rate to 16.5% and reduced the price of the
warrants from an initial strike price of $41.04 per share to $20.88 per share.

In April 2002, the Company entered into an additional amendment to the Levine
Note. In connection with the amendment, the lender reset all covenants for 2002
and subsequent years, in addition to certain other modifications. As
consideration for the amendment, the Company has agreed to pay an amendment fee
of $2,000, payable in additional notes and increase the PIK interest rate by
one-half percentage point. The amendment fee has been capitalized and is being
amortized over the remaining life of the Levine Note.

The entire principal of the Levine Note is due September 2005 but may be paid
earlier at the Company's election, subject to a prepayment penalty.
Additionally, the Levine Note has mandatory principal prepayments based upon a
change in ownership, certain asset sales, or excess cash flows. The Levine Note
bears interest at 12.5%, payable monthly, with an option to pay the interest in
a PIK note. The Company is currently issuing PIK notes at 17.0% for payment of
current interest amounts owed. The Securities Purchase Agreement contains
covenants, including but not limited to, restricting the Company's ability to
incur certain indebtedness, liens or investments, restrictions relating to
agreements affecting capital stock, maintenance of a specified net worth and
compliance with specified financial ratios.

In 1998, the Company issued $30,000 of subordinated convertible notes
("Convertible Notes"). The Convertible Notes mature June 2006 and currently bear
interest at 8.0%, payable semi-annually with an option to pay the interest in a
PIK note also bearing interest at 8.0%, which the Company is currently
exercising for payment of current interest amounts due. In April 2001, the
Company entered into an amendment to the Convertible Notes and the lender waived
the cross-default provision that existed at December 31, 2000 due to the
covenant violations under the Credit Facility and agreed to reset all covenants
for 2001 and subsequent years, in addition to certain other modifications. As
consideration for the amendment, the Company has agreed to reduce the conversion
price of the notes. The Convertible Notes are convertible into shares of the
common stock at $39.00 for each share of common stock issuable upon conversion
of outstanding principal and accrued but unpaid interest on such subordinated
notes and shall be automatically converted into common stock if the rolling
21-day average closing market price of the common stock on 20 out of any 30
consecutive trading days is more than $107.40

(6)      SHAREHOLDERS' EQUITY

The Company made advances of $11,500 to certain officers of the Company and
provided certain other officers with a minimum guarantee of the value of their
stock options in order to retain and provide incentives to such officers. In
connection with the advances, such officers issued interest-bearing notes
payable to the Company. Shares of the Company's common stock and options owned
by such officers have been pledged to secure the notes. The notes were included
in shareholders' equity as a reduction to equity. Interest on the notes accrues
at rates ranging from 6.4% to 10.2%. The notes and accrued interest are due June
2004, payable in cash or Company common stock and options with varying minimum
values. The notes and accrued interest were with recourse to the officers until
May or June of 2002, depending upon the individual note agreement, after which
the notes and accumulated interest became non-recourse, subject only to the
underlying pledged collateral.

The difference in the amount of the notes and the value of the collateral at the
date of the loans was being amortized over the life of the notes, representing
stock compensation expense. The amortization reflected the deficit of the
underlying pledged collateral on the individual note dates. The Company also
adjusted the amortization to reflect changes in the quoted fair market value.
The decline, if any, was amortized as stock compensation expense over the life
of the notes. The amortization expense was adjusted cumulatively for changes in
fair value of the collateral. Increases in the stock price, if any, resulted in
a credit to expense, up to the amount of prior expense recognized for this
portion of the notes. In addition, the minimum guarantee of the value of the
stock options was being amortized as stock compensation expense.


The total advance included loans to certain DCA officers. The non-amortized
balance of the advances to DCA officers of $4,600 was sold in connection with
the sale of DCA. Also, during the third quarter of 2001, the entire
non-amortized balance of the remaining notes was written off as a result of the
acceleration of the non-recourse provision of the note due from the former CEO
and the significant decline in the underlying value of the pledged collateral,
which is considered to be other than temporary.

Also, in connection with the execution of an officer's amended employment
agreement, a note receivable and related accrued interest of $182 were to be
forgiven, subject to provisions of the agreement. The note and accrued interest
were being expensed over the twenty-four month service period ending May 2002.
During the third quarter of 2001, the remaining balance on the note was written
off as compensation expense based on the note being converted to non-recourse
pursuant to the severance agreement with the officer.

(7)      CONTINGENCIES

On November 28, 2000, the Court entered its Order of Related Cases with regard
to an action previously filed by InterDent on September 28, 2000 in Los Angeles
Superior Court Case No. BC237600, wherein InterDent alleged causes of action
against Amerident for breach of contract, breach of the implied covenant of good
faith and fair dealing, intentional misrepresentation and negligent
misrepresentation. On October 18, 2000, Amerident Dental Corp. ("Amerident")
filed a lawsuit against InterDent and Gentle Dental Management, Inc. seeking
damages related to the July 21, 1999 sale of substantially all of the assets of
ten dental practices in California and Nevada. On January 19, 2001, Amerident
filed another action against InterDent and Gentle Dental Management, Inc. for
Breach of a Promissory Note and related common counts, that action was similarly
deemed related and consolidated with the earlier filed InterDent action.
Discovery is ongoing. The trial began July 2002 and is currently in process.
InterDent believes that this case is without merit and intends to vigorously
defend all allegations. Accordingly, no liability for this suit has been
recorded at this time.

The Company has been named as a defendant in various other lawsuits in the
normal course of business, primarily for malpractice claims. The Company and
affiliated dental practices, and associated dentists are insured with respect to
dentistry malpractice risks on a claims-made basis. Management believes all of
these pending lawsuits, claims, and proceedings against the Company are without
merit or will not have a material adverse effect on the Company's consolidated
operating results, liquidity or financial position.







<PAGE>




Item 2.  Management's Discussion and Analysis of Financial Condition and Results
         of Operations

Forward-looking and Cautionary Statements

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor"
for certain forward-looking statements. Certain information included in this
Form 10-Q and other materials filed with the Securities and Exchange Commission
(as well as information included in oral statements or other written statements
made or to be made by the Company) contain statements that are forward looking,
such as statements relating to business strategies, plans for future development
and upgrading, capital spending, financing sources, changes in interest rates,
and the effects of regulations. Such forward-looking statements involve
important known and unknown risks and uncertainties that could cause actual
results and liquidity to differ materially from those expressed or anticipated
in any forward-looking statements. Such risks and uncertainties include, but are
not limited to: those related to the effects of competition; leverage and debt
service; financing needs or efforts; actions taken or omitted to be taken by
third parties, including the Company's customers, suppliers, competitors, and
stockholders, as well as legislative, regulatory, judicial, and other
governmental authorities; changes in business strategy; general economic
conditions; changes in health care laws, regulations or taxes; risks related to
development and upgrading systems; and other factors described from time to time
in the Company's reports filed with the Securities and Exchange Commission.
Accordingly, actual results may differ materially from those expressed in any
forward-looking statement made by or on behalf of the Company. Any
forward-looking statements are made pursuant to the Private Securities
Litigation Reform Act of 1995, and, as such, speak only as of the date made. The
Company undertakes no obligation to revise publicly these forward-looking
statements to reflect subsequent events or circumstances

Overview

We are a leading provider of dental practice management services to
multi-specialty dental professional corporations and associations ("PAs") in the
United States. The dentists employed through our network of affiliated PAs
provide patients with affordable, comprehensive, convenient and high quality
dentistry services, which include general dentistry, endodontics, oral
pathology, oral surgery, orthodontics, pedodontics, periodontics and
prosthodontics.

Through May 31, 2001, we provided management services to dental practices in
Arizona, California, Florida, Georgia, Hawaii, Idaho, Indiana, Kansas, Maryland,
Michigan, Nevada, Oklahoma, Oregon, Pennsylvania, Virginia and Washington.
Effective May 31, 2001, we completed the sale of all of the common stock of
Dental Care Alliance, Inc. ("DCA"), a wholly-owned subsidiary, and certain other
assets in Maryland, Virginia, and Indiana. Total consideration was $36.0
million, less the assumption of related debt and operating liabilities. The net
sales proceeds were utilized to pay down existing borrowings under our credit
facility. We also have retained an option to repurchase the division at a future
date and entered into an ongoing collaboration agreement and license agreement
to provide our proprietary software. As of June 30, 2002 we provided management
services to 140 dental offices that employ 536 dentists, including 105
specialists. We currently operate in Arizona, California, Hawaii, Idaho, Kansas,
Nevada, Oklahoma, Oregon, and Washington.

We have historically affiliated with PAs by purchasing the operating assets of
those practices, including furniture and fixtures, equipment and instruments,
and entering into long-term (typically 40 years) management service agreements
("MSAs") with the PAs associated with the practice. Under the terms of these
agreements, we are the exclusive administrator of all non-clinical aspects of
the dental practices, whereas the affiliated PAs are exclusively in control of
all aspects of the practice and delivery of dental services. As compensation for
services provided under the MSAs, we receive a management fee typically equal to
the reimbursement of expenses incurred in operating the practice plus a
percentage of the net revenues of the affiliated dental practice.

As compensation for services provided under the MSAs, we receive management fees
from our affiliated dental practices. Depending upon the individual MSA
provisions, the management fee is calculated based upon one of two methods.
Under one method, the management fee is equal to reimbursement of expenses
incurred in the performance of our obligations under the management service
agreements, plus an additional fee equal to a percentage of the net revenues of
the affiliated dental practices. Under the other method, the management fee is a
set percentage of the net revenues of the affiliated dental practices.

The Emerging Issues Task Force ("EITF") of the Financial Accounting Standards
Board reached a consensus on the accounting for transactions between physician
practice management companies and physician practices and the financial
reporting of such entities (EITF issue number 97-2). For financial reporting
purposes, EITF 97-2 mandates the consolidation of physician practice activities
with the practice management company when certain conditions have been met, even
though the practice management company does not have a direct equity investment
in the physician practice. The accompanying condensed consolidated financial
statements are prepared in conformity with the consensus reached in EITF 97-2.

Simultaneous to the execution of an MSA with each PA, we also entered into a
shares acquisition agreement ("SAA"). Subsequent to the sale of DCA, under all
of the SAAs entered into except for one, we have the right to designate the
purchaser (successor dentist) to purchase from the PA shareholders all the
shares of the PA for a nominal price of $1,000 or less. Under these SAAs, we
have the unilateral right to establish or effect a change in the PA shareholder,
at will, and without consent of the PA shareholder, on an unlimited basis. Under
the provisions of EITF 97-2, the agreements with the PA shareholders qualify as
a friendly doctor arrangement. Consequently, under EITF 97-2, we consolidate all
the accounts of those PAs in the accompanying condensed consolidated financial
statements. Accordingly, the condensed consolidated statements of operations
include the net patient service revenues and related expenses of these PAs and
all significant intercompany transactions have been eliminated.

Each of the DCA SAAs entered into with the PAs did not have the nominal price
provision. Also, subsequent to the DCA sale one remaining SAA entered into with
a PA does not have the nominal price provision. Rather, the SAA purchase price
is based upon a multiple of earnings, as defined. As a result, the agreements do
not meet the criteria of consolidation under EITF 97-2 and the condensed
consolidated statements of operations exclude the net patient service revenues
and expenses of these PAs. The condensed consolidated statements of operations
include only our net management fee revenues generated and expenses associated
with providing services under the MSAs.

Critical Accounting Policies and Estimates

The preparation of our condensed consolidated financial statements requires
management to make estimates and judgments that affect the reported amounts of
assets, liabilities and revenues and expenses. On an on-going basis we evaluate
these estimates, including those related to the carrying the value of accounts
receivables, intangible and long-lived assets, income taxes and any potential
future impairment. We base our estimates on historical experience and on various
other assumptions that are believed to be reasonable under the circumstances,
the results of which form the basis for making judgments about carrying values
of assets and liabilities that are not readily apparent from other sources.
Actual results may differ from these estimates under different assumptions or
conditions.

We have identified the policies below as critical to our business operations and
the understanding of our results of operations:

Valuation of accounts receivables. The carrying amount of accounts receivables
requires management to assess the future collectibility of our accounts
receivables and establish an allowance for patients covered by third-party payor
contracts, anticipated discounts and doubtful accounts. Our established
allowance is determined based upon historical realization rates, the current
economic environment and the age of accounts. Changes in our estimated
collection rates are recorded as a change in estimate in the period the change
is made.

Intangibles and long-lived Assets. Our business acquisitions typically result in
intangible and long-lived assets. Effective January 1, 2002, we adopted FASB
Statement of Financial Accounting Standard No. 142, "Goodwill and Other
Intangible Assets" ("SFAS 142"). Under SFAS 142, our service mark, MSAs and
goodwill intangible assets are no longer amortized but are reviewed annually for
impairment. The determination of the value of such intangible assets, utilized
for determining whether impairment exits, requires management to make estimates
and assumptions that affect our consolidated financial statements. We are
currently performing the required impairment tests of goodwill and indefinite
lived intangible assets as of January 1, 2002. We have completed the first step
of the two-step transitional impairment analysis required by SFAS 142. This
analysis indicated that the carrying amount of our net assets exceeds the fair
value. Preliminary results of the second step of the transitional impairment
analysis indicates that an impairment charge totaling $50 to $100 million will
be required, although such analysis in not complete. We expect to complete this
analysis in the fourth quarter of 2002.

Income Taxes. We record a valuation allowance to reduce our deferred income tax
assets to the amount that is more likely than not to be realized. Our assessment
of the realization of deferred income tax assets requires that estimates and
assumptions be made as to taxable income of future periods. Projection of future
period earnings is inherently difficult as it involves consideration of numerous
factors such as our overall strategies, market growth rates, responses by
competitors, assumptions as to operating expenses and other industry specific
factors.

Results of Operations

The following discussion highlights changes in historical revenues and expense
levels for the three and six-month period ended June 30, 2002, compared to the
three and six-month period ended June 30, 2001, as reported in our condensed
consolidated financial statements and the related notes thereto appearing
elsewhere herein.

Three  Months  Ended June 30, 2002  Statement  of  Operations  Compared to Three
Months Ended June 30, 2001

Dental Practice Net Patient Service Revenue. Dental practice net patient service
revenue represents the clinical patient revenues at affiliated dental practices
where the consolidation requirements of EITF 97-2 have been met. There were 166
such clinical locations through May 31, 2001 and 146 such locations immediately
subsequent to the DCA sale transaction, and 139 such locations at June 30, 2002.
Dental practice net patient service revenue was $64.1 million for 2002 compared
to $68.0 million for 2001, representing a 5.7% decrease.

This revenue decrease is due to the sale of 21 clinical locations during fiscal
2001, including 15 locations sold as part of the DCA sale on May 31, 2001. For
those locations affiliated as of January 1, 2001, where the management service
agreements meet the EITF criteria for consolidation, same-store dental practice
net patient service revenue for 2002 increased by approximately 0.5% when
compared to revenue for 2001.

Net Management Fees. Net management fees consist of revenue earned in the
performance of our obligations under management service agreements at affiliated
dental practices where the consolidation requirements of EITF 97-2 are not met.
The decrease in these revenues, $0.19 million in 2002 as compared to $8.0
million in 2001, is entirely related to the DCA sale transaction as essentially
all of our management fees revenues were earned by our DCA subsidiary. There
were 78 such clinical locations through May 31, 2001 and 2 such locations
subsequent to the DCA sale transaction through May 2002, and 3 locations
effective June 1, 2002.

Licensing and Other Fees. We earn certain fees from unconsolidated affiliated
dental practices for various licensing and consulting services. These revenues
were approximately $0.20 million for 2002 and 2001.

Practice Operating Expenses. Practice operating expenses represent the direct
costs associated with operating and managing the practice facility locations,
including regional support departments. These costs are comprised of the
following expenses:

     Clinical Salaries, Benefits and Provider Costs include all patient service
     provider staff compensation and related payroll costs at the consolidated
     affiliated dental practices, including dentists, hygienists and dental
     assistants, and dental assistants for the unconsolidated affiliated dental
     practices;

     Practice Non-clinical Salaries and Benefits include all staff compensation
     and related payroll costs at all dental and regional facilities other than
     dentists, hygienists, and dental assistants;

     Dental Supplies and Lab Expenses include all direct supply costs in the
     performance of patient treatment programs;

     Practice Occupancy Expenses include facility leases, property taxes,
     utilities, janitorial services, repairs and maintenance; and

     Practice Selling, General, and Administrative Expenses include general
     office, advertising, professional services (excluding dentistry), office
     supplies, bank processing fees, local taxes, insurance, bad debt expense,
     and other miscellaneous costs at the dental facilities and regional
     centers.

Practice operating expenses were $55.2 million for 2002 compared to $65.7
million for 2001, representing a 16.0% decrease. The decrease in practice
operating expenses is primarily due to the sale of the DCA subsidiary on May 31,
2001 and six clinical locations disposed of during the second half of 2001.

Excluding all revenues and expenses of the offices disposed of during 2001,
practice operating expenses at the remaining offices (the "Remaining Offices")
for 2002 were 86.0% of total revenue compared to 86.2% for 2001. The practice
operating margin at the Remaining Offices for 2002 was 14.0% compared to 13.8%
for 2001. The increase in operating margin resulted from a decrease in
nonclinical salaries and benefits, dental and lab supplies, occupancy, and SG&A
costs at the Remaining Offices, as a percent of revenues, offset by an increase
clinical salaries, benefits and provider costs. We are seeking to reduce
clinical costs as a percentage of revenue by a combination of revenue
enhancement and cost cutting initiatives. Such costs are expected to decline as
a percent of revenue and reflect costs in line with our better practices once
our initiatives are completed.

Corporate Selling, General and Administrative Expenses. Corporate selling,
general and administrative expenses include: corporate salaries, general office
costs, investor relations expense, legal and audit fees, general insurance,
director and officer liability insurance, corporate office supplies, and other
miscellaneous costs at our corporate facilities. Corporate selling, general and
administrative expenses were $3.1 million for 2002 compared to $3.5 million for
2001, representing a 12.7% decrease. The decrease in total corporate selling,
general and administrative expenses is the result of implementation of strategic
management initiatives in corporate staffing levels in our accounting and
finance, plan management, operations, human resource, and other corporate
support departments to leverage cost effective solutions in solving the
infrastructure needs of the Company.

Stock Compensation Expense. During the second and third quarter of 2000, we
advanced $11.5 million under notes that became non-recourse after two years to
certain officers in order to retain and provide incentives to such officers,
where shares of our stock owned by each officer serve as collateral for the
advances. The entire balance was recorded as deferred compensation in
shareholders' equity in the condensed consolidated balance sheets. The deferred
compensations was being amortized over the life of the advances as stock
compensation expense, representing the difference in the amount of the advances
and the value of the collateral at the date of the loans. The total original
advance included advances of $5.9 million to DCA officers. These advances were
sold in connection with the sale of DCA. The remaining non-amortized outstanding
balance of deferred compensation associated with the advances to DCA officers at
the time of the sale transaction was $4.6 million. During the third quarter of
2001, the entire remaining non-amortized balance of deferred compensation was
written off as a result of the acceleration of the non-recourse provision of the
advance due from the former CEO and the significant decline in the underlying
value of the pledged collateral, which was considered to be other than
temporary.

In connection with the execution of an officer's amended employment agreement, a
note receivable and related accrued interest of approximately $0.20 million were
to be forgiven, subject to provisions of the agreement. The note and accrued
interest were being expensed over the twenty-four month service period ending
May 2002. During the third quarter of 2001, the remaining balance on the note
was written off as compensation expense based on the note being converted to
non-recourse pursuant to the severance agreement with the officer. In 2000 we
also began accruing for a stock based incentive program to certain employees
that was paid in June 2002.

For 2002, we recorded total stock compensation expense of $0.07 million as
compared to $0.85 million for 2001. No additional stock compensation expense is
anticipated in 2002.

(Gain) loss on dental location dispositions and impairment of long-lived assets.
For 2002, we recognized a gain of $0.19 million, representing $0.32 million in
insurance reimbursement relating the sale of certain dental locations in 2002,
which was partially offset by a recorded loss of $0.13 upon consummation of the
sale of an additional dental location in June 2002. For 2001, we completed a
stock sale of DCA, a wholly-owned subsidiary, and certain other assets in
Maryland, Virginia, and Indiana for total consideration of $36 million,
including cash of $26.5 million and the assumption of related debt and operating
liabilities, and a license fee of $2.6 million, payable in future installments.
The loss of $5.9 million recorded in 2001 included a provision for transaction
related closing costs.

Depreciation and Amortization. Depreciation and amortization was $1.0 million
for 2002 compared to $3.2 million for 2001. Of this decrease of $2.2 million,
$0.39 million is due to depreciation and amortization associated with the sale
of DCA and $1.8 million as a result of the implementation of FASB issued
Statement of Financial Accounting Standard No. 142, "Goodwill and Other
Intangible Assets", which eliminated the amortization of our intangible assets
as discussed in Note 2 to the accompanying condensed consolidated financial
statements.

Interest Expense. Interest expense, net of interest income, was $5.8 million for
2002 compared to $5.2 million for 2001. In April 2002 and 2001, we entered into
various amendments to our outstanding Credit Facility and Levine Notes, as
further described in note 5 to the condensed consolidated financial statements.
These amendments increased our borrowing costs due to escalations in interest
rates and the amortization of deferred closing costs over the life of the loans.
These increases were partially offset by a reduction in borrowings under the
credit facility (the "Credit Facility") as a result of the principal payments
made in 2001 in connection with the sale of DCA.

Debt and equity financing costs. In April 2001, we entered into various
amendments to our existing Credit Facility and convertible senior subordinate
debt as described in note 5 to the condensed consolidated financial statements.
As a result, we recorded a charge of $3.9 million for the write-off of certain
prepaid debt costs related to previously entered credit facility agreements,
loan amendment fees, warrant issuance valuations, and associated professional
fees incurred in connection with the execution of the various loan amendments.

Extraordinary loss on debt extinguishments. In April 2002, we entered into an
additional amendment to the Credit Facility. The amendment meets the criteria of
substantial modification as outlined in EITF 96-19. As such, the original Credit
Facility is considered extinguished, with a new Credit Facility issued in its
place. Accordingly, we recorded an extraordinary charge of $2.6 million for
2002. No tax benefit was recorded as a result of the charge as the realization
of available deferred tax assets is not assured. The extraordinary loss
represents the amendment fees of $2.0 million incurred and $0.60 million for the
write-off of the non-amortized portions of previously recorded deferred
financing costs associated with the original facility agreement.

In April 2001, we entered into an agreement to amend our senior subordinated
debt ("Levine Note"). The amendment to the Levine Note met the criteria of
substantial modification as outlined in EITF 96-19, resulting in an
extraordinary charge of $5.6 million for 2001. No tax benefit was recorded as a
result of the charge as the realization of available deferred tax assets is not
assured. The extraordinary loss represents the amendment fee of $2.2 million
incurred to extinguish the original note and $3.4 million for the write-off of
the non-amortized portions of warrant discount and deferred financing costs also
associated with the original note agreement

Provision for Income Taxes. Our statutory tax rate for federal and state
purposes is approximately 40%. The income tax expense of $0.03 million for 2002
and $0.05 million for 2001 represents our estimated state tax payable. We expect
to utilize existing loss carryforwards to offset any federal tax payable for
2002 and 2001.


Six Months Ended June 30, 2002  Statement of  Operations  Compared to Six Months
Ended June 30, 2001

Dental Practice Net Patient Service Revenue. Dental practice net patient service
revenue represents the clinical patient revenues at affiliated dental practices
where the consolidation requirements of EITF 97-2 have been met. There were 166
such clinical locations through May 31, 2001 and 146 such locations immediately
subsequent to the DCA sale transaction, and 139 such locations at June 30, 2002.
Dental practice net patient service revenue was $127.5 million for 2002 compared
to $139.9 million for 2001, representing an 8.9% decrease.

This revenue decrease is due to the sale of 21 clinical locations during fiscal
2001, including 15 locations sold as part of the DCA sale on May 31, 2001. For
those locations affiliated as of January 1, 2001, where the management service
agreements meet the EITF criteria for consolidation, same-store dental practice
net patient service revenue for 2002 increased by approximately 1.5% when
compared to revenue for 2001.

Net Management Fees. Net management fees consist of revenue earned in the
performance of our obligations under management service agreements at affiliated
dental practices where the consolidation requirements of EITF 97-2 are not met.
The decrease in these revenues, $0.39 million in 2002 as compared to $19.6
million in 2001, is entirely related to the DCA sale transaction as essentially
all of our management fees revenues were earned by our DCA subsidiary. There
were 78 such clinical locations through May 31, 2001 and 2 such locations
subsequent to the DCA sale transaction through May 2002, and 3 locations
effective June 1, 2002.

Licensing and Other Fees. We earn certain fees from unconsolidated affiliated
dental practices for various licensing and consulting services. These revenues
were approximately $0.40 million for 2002 and 2001.

Practice Operating Expenses. Practice operating expenses represent the direct
costs associated with operating and managing the practice facility locations,
including regional support departments. These costs are comprised of the
following expenses:

     Clinical Salaries, Benefits and Provider Costs include all patient service
     provider staff compensation and related payroll costs at the consolidated
     affiliated dental practices, including dentists, hygienists and dental
     assistants, and dental assistants for the unconsolidated affiliated dental
     practices;

     Practice Non-clinical Salaries and Benefits include all staff compensation
     and related payroll costs at all dental and regional facilities other than
     dentists, hygienists, and dental assistants;

     Dental Supplies and Lab Expenses include all direct supply costs in the
     performance of patient treatment programs;

     Practice Occupancy Expenses include facility leases, property taxes,
     utilities, janitorial services, repairs and maintenance; and

     Practice Selling, General, and Administrative Expenses include general
     office, advertising, professional services (excluding dentistry), office
     supplies, bank processing fees, local taxes, insurance, bad debt expense,
     and other miscellaneous costs at the dental facilities and regional
     centers.

Practice operating expenses were $110.0 million for 2002 compared to $137.0
million for 2001, representing a 19.7% decrease. The decrease in practice
operating expenses is primarily due to the sale of the DCA subsidiary on May 31,
2001 and six clinical locations disposed of during the second half of 2001.

Excluding all revenues and expenses of the offices disposed of during 2001,
practice operating expenses at the remaining offices (the "Remaining Offices")
for 2002 were 85.8% of total revenue compared to 86.3% for 2001. The practice
operating margin at the Remaining Offices for 2002 was 14.2% compared to 13.7%
for 2001. The increase in operating margin resulted from a decrease in
nonclinical salaries and benefits, dental and lab supplies, occupancy, and SG&A
costs at the Remaining Offices, as a percent of revenues, offset by an increase
clinical salaries, benefits and provider costs. We are seeking to reduce
clinical costs as a percentage of revenue by a combination of revenue
enhancement and cost cutting initiatives. Such costs are expected to decline as
a percent of revenue and reflect costs in line with our better practices once
our initiatives are completed.

Corporate Selling, General and Administrative Expenses. Corporate selling,
general and administrative expenses include: corporate salaries, general office
costs, investor relations expense, legal and audit fees, general insurance,
director and officer liability insurance, corporate office supplies, and other
miscellaneous costs at our corporate facilities. Corporate selling, general and
administrative expenses were $7.3 million for 2002 compared to $6.7 million for
2001, representing an 8.4% increase. The increase in total corporate selling,
general and administrative expenses is the result of $0.45 million relating to
consulting fees associated with our operational improvement initiatives
discussed in the liquidity section below, the majority of which were incurred
during the first three months of 2002.

Stock Compensation Expense. During the second and third quarter of 2000, we
advanced $11.5 million under notes that became non-recourse after two years to
certain officers in order to retain and provide incentives to such officers,
where shares of our stock owned by each officer serve as collateral for the
advances. The entire balance was recorded as deferred compensation in
shareholders' equity in the Condensed Consolidated Balance Sheets. The deferred
compensation was being amortized over the life of the advances as stock
compensation expense, representing the difference in the amount of the advances
and the value of the collateral at the date of the loans. The total original
advance included advances of $5.9 million to DCA officers. These advances were
sold in connection with the sale of DCA. The remaining non-amortized outstanding
balance of deferred compensation associated with the advances to DCA officers at
the time of the sale transaction was $4.6 million. During the third quarter of
2001, the entire remaining non-amortized balance of deferred compensation was
written off as a result of the acceleration of the non-recourse provision of the
advance due from the former CEO and the significant decline in the underlying
value of the pledged collateral, which was considered to be other than
temporary.

In connection with the execution of an officer's amended employment agreement, a
note receivable and related accrued interest of approximately $0.20 million were
to be forgiven, subject to provisions of the agreement. The note and accrued
interest were being expensed over the twenty-four month service period ending
May 2002. During the third quarter of 2001, the remaining balance on the note
was written off as compensation expense based on the note being converted to
non-recourse pursuant to the severance agreement with the officer. In 2000 we
also began accruing for a stock based incentive program to certain employees
that was paid in June 2002.

For 2002, we recorded total stock compensation expense of $0.15 million as
compared to $1.7 million for 2001. No additional stock compensation expense is
anticipated in 2002.

(Gain) loss on dental location dispositions and impairment of long-lived assets.
For 2002, we recognized a gain of $0.19 million, representing $0.32 million in
insurance reimbursement relating the sale of certain dental locations in 2002,
which was partially offset by a recorded loss of $0.13 upon consummation of the
sale of an additional dental location in June 2002. For 2001, we completed a
stock sale of DCA, a wholly-owned subsidiary, and certain other assets in
Maryland, Virginia, and Indiana for total consideration of $36 million,
including cash of $26.5 million and the assumption of related debt and operating
liabilities, and a license fee of $2.6 million, payable in future installments.
The loss of $5.9 million recorded in 2001 included a provision for transaction
related closing costs.

Depreciation and Amortization. Depreciation and amortization was $2.0 million
for 2002 compared to $6.4 million for 2001. Of this decrease of $4.4 million,
$0.92 million is due to depreciation and amortization associated with the sale
of DCA and $3.4 million as a result of the implementation of FASB issued
Statement of Financial Accounting Standard No. 142, "Goodwill and Other
Intangible Assets", which eliminated the amortization of our intangible assets
as discussed in note 2 to the accompanying condensed consolidated financial
statements.

Interest Expense. Interest expense, net of interest income, was $10.2 million
for 2002 compared to $10.7 million for 2001. In April 2002 and 2001, we entered
into various amendments to our outstanding Credit Facility and Levine Notes, as
further described in note 5 to the condensed consolidated financial statements.
These amendments increased our borrowing costs due to escalations in interest
rates and the amortization of deferred closing costs over the life of the loans.
These increases were partially offset by a reduction in borrowings under the
credit facility (the "Credit Facility") as a result of the principal payments
made in 2001 in connection with the sale of DCA.

Debt and equity financing costs. In April 2001, we entered into various
amendments to our existing Credit Facility and convertible senior subordinate
debt as described in note 5 to the condensed consolidated financial statements.
As a result, we recorded a charge of $3.9 million for the write-off of certain
prepaid debt costs related to previously entered credit facility agreements,
loan amendment fees, warrant issuance valuations, and associated professional
fees incurred in connection with the execution of the various loan amendments.

Extraordinary loss on debt extinguishments. In April 2002, we entered into an
additional amendment to the Credit Facility. The amendment meets the criteria of
substantial modification as outlined in EITF 96-19. As such, the original Credit
Facility is considered extinguished, with a new Credit Facility issued in its
place. Accordingly, we recorded an extraordinary charge of $2.6 million for
2002. No tax benefit was recorded as a result of the charge as the realization
of available deferred tax assets is not assured. The extraordinary loss
represents the amendment fees of $2.0 million incurred and $0.60 million for the
write-off of the non-amortized portions of previously recorded deferred
financing costs associated with the original facility agreement.

In April 2001, we entered into an agreement to amend our senior subordinated
debt ("Levine Note"). The amendment to the Levine Note met the criteria of
substantial modification as outlined in EITF 96-19, resulting in an
extraordinary charge of $5.6 million for 2001. No tax benefit was recorded as a
result of the charge as the realization of available deferred tax assets is not
assured. The extraordinary loss represents the amendment fee of $2.2 million
incurred to extinguish the original note and $3.4 million for the write-off of
the non-amortized portions of warrant discount and deferred financing costs also
associated with the original note agreement

Provision for Income Taxes. Our statutory tax rate for federal and state
purposes is approximately 40%. The income tax expense of $0.06 million for 2002
and $0.10 million for 2001 represents our estimated state tax payable. We expect
to utilize existing loss carryforwards to offset any federal tax payable for
2002 and 2001.


Liquidity and Capital Resources

Liquidity

We have experienced losses attributed to common stock of $4.3 million the six
months ended June 30, 2002 and for fiscal years ended 2001 and 2000, $35.1
million and $48.7 million, respectively. These past significant losses included
certain charges for asset impairments, disposition of DCA and certain other
dental locations, and debt restructuring and debt extinguishments, which we
believe are unusual in nature. Although we have experienced losses over the two
years ended December 31, 2001 due to these unusual charges, our dental
facilities continue to generate significant positive cash, as reflected in cash
flows from operations of $7.2 million for the six months ended June 30, 2002 and
for fiscal years ended 2001 and 2000, $19.4 million and $9.5 million,
respectively.

During 2001, we hired an advisor to review our operations to determine whether
improvements could be made, which could be implemented in the near and long
term. The advisor, along with our personnel, reviewed such strategies as revenue
enhancements, modifications to managed care contracts, savings from procurement
efficiencies, and reduction of headcount at dental office and corporate
locations. As a result of this review, a number of initiatives to improve
operations were implemented in late 2001 and early 2002. These initiatives are
projected to increase cash flow in 2002 and in future periods through our
emphasis on increasing same store revenues and curtailing direct operating
costs. Through June 30, 2002, we have met our earning projections.

These initiatives and the projected improvements in operations and cash flows
played a vital role in our ability to negotiate modifications to our credit
agreement that was consummated on April 15, 2002, as more fully described in
Note 5 to the notes to the condensed consolidated financial statements. These
modifications resulted in a permanent waiver of our past covenant violations,
and reset the covenants to levels, which our projections indicate will be met
throughout all of 2002. We also incurred certain fees and expenses, and the
interest rate was increased by 1%. In addition, the principal amortization
schedule was significantly modified such that approximately $20.7 million of
payments due through March 31, 2003 were deferred until the second quarter 2003,
and only $7.9 million of principal payments are due through June 30, 2003. We
paid the $2.4 million scheduled installment due April 1, 2002.

Management believes that we will be able to make all scheduled debt payments
through March 31, 2003, and those due under earn-out agreements, along with
meeting other obligations. Further, we have significant debt due beginning April
1, 2003, which must be refinanced, modified, or otherwise retired with the
proceeds of other financing or capital transactions. There can be no assurance
that we will meet its obligations through March 31, 2003, and that any such
financing will be available or available on terms acceptable to InterDent.

Current Financial Condition and Cashflows

At June 30, 2002, cash and cash equivalents were $5.6 million, representing a
$1.6 million decrease in cash and cash equivalents from $7.2 million at December
31, 2001. The decrease is primarily due to the pay down of accounts payable and
our outstanding Credit Facility. Our working capital deficit at June 30, 2002 of
$18.1 million represents an increase from a working capital deficit at December
31, 2001 of $6.3 million. The increase in the working capital deficit is
primarily due to a $5.7 million increase in the current portion of long-term
debt and capital lease obligations and $4.4 million in accrued Credit Facility
fees to be paid in 2002 and 2003, as discussed in note 5 to the condensed
consolidated financial statements.

Net cash provided by operations amounted to $7.2 million for 2002 compared to
$12.7 million for 2001. The decrease in net cash provided by operations is
primarily attributed to $5.6 million in net cash used for accounts payable
activity between the two periods. Additionally, during 2001 we received an
income tax refund of $1.4 million.

Net cash used in investing activities was $1.4 million for 2002 as compared to
cash provided by investing activities of $13.4 million for 2001. Included in the
investing activities for 2002 is cash paid of $1.2 million for earnout and other
payments on affiliated dental practice acquisitions that closed in prior years.
Cash paid for earnouts and acquisition closing costs were $3.6 million for 2001.
Proceeds from the disposition of dental locations were $0.60 million in 2002
compared to $22.1 million in 2001. The 2001 proceeds were primarily associated
with the DCA sale transaction in May 2001. We also paid $0.80 million for
property and equipment for 2002 compared to $2.1 million for 2001. There were no
advances to unconsolidated affiliated practices in 2002 and $3.2 million for
2001. Advances consisted primarily of receivables from PAs due in connection
with cash advances for working capital and operating purposes to certain
unconsolidated PAs. We advanced funds to these certain PAs during the initial
years of operations, until the PA owner could repay the seller debt, and the
operations improve. Such advances entirely related to our DCA division
facilities, which were eliminated upon consummation of the DCA stock sale
transaction in May 2001.

Net cash used in financing activities was $7.4 million for 2002, comprising of
$6.1 million in debt payments and $1.3 million for payments of deferred
financing costs associated with the amendment to the Credit Facility and Levine
Note that consummated in April 2002. Cash used in financing activities for 2001
was $28.3 million and primarily related to $25.6 million net debt payments from
the DCA sale and $2.3 million in deferred financing costs associated with the
amendment to the Credit Facility and Levine Note that consummated in April 2001.

In connection with certain completed affiliation transactions, we have agreed to
pay to the sellers' future consideration. The amount of future consideration
payable under earn-outs is generally computed based upon financial performance
of the affiliated dental practices during certain specified periods. We accrue
for earn-out payments with respect to these acquisitions when such amounts are
probable and reasonably estimable. In addition to cash earn-out payments of
$0.94 million during the six months ended June 30, 2002, we also converted $1.1
million in earn-out amounts due into long-term notes payable. As of June 30,
2002, future anticipated earn-out payments of $2.8 million are accrued and
included in other current liabilities. For those acquisitions with earn-out
provisions, we estimate the total maximum earn-out that could be paid, including
amounts already accrued, is between $5.0 and $6.0 million from July 2002 to
December 2005, which is expected to be paid in a combination of cash and notes.

Outstanding Debt and Other Financing Arrangements

         Credit Facility Term Note

In April 2001, we entered into amendments to its existing senior revolving
credit facility (the "Credit Facility") to amend certain covenants. In
connection with the execution of the amendments, the banks waived the defaults
under the Credit Facility that existed at December 31, 2000 due to failure to
meet certain financial ratio covenants and reset all covenants for 2001 and
subsequent years. Additionally, the banks agreed to certain other changes
including a revised term and provisions regarding asset sales and new financing.

As consideration for these modifications, we agreed to an amendment fee of $1.0
million, which was paid during the three months ended June 30, 2001, and an
additional fee of $1.0 million payable at maturity of the term loan if certain
conditions are not met. The additional fee was paid in connection with an
additional amendment to the Credit Facility consummated in April 2002, as
discussed below.

On October 1, 2001, our Credit Facility converted into a term loan, with
required quarterly payments. On April 15, 2002, we entered into an amendment to
our Credit Facility, which has an outstanding balance of $79.4 million. In
connection with the execution of the amendment, the bank agreed, among other
things, to reset certain covenants and reduce the required future quarterly
principal payments of $7.2 million, which began on October 1, 2001. In
connection with these modifications, we accrued as note principal the remaining
$1.0 million due as a result of an amendment conducted in April 2001, which is
payable upon maturity. We also agreed to an additional amendment fee of $1.0
million, with cash of $0.50 million payable at closing and $0.25 million to
accrue as additional principal on July 1, 2002 and October 1, 2002, payable upon
final maturity of the Credit Facility on September 30, 2003. The July 1 and
October 1, 2002 accrual dates are subject to change, as outlined in the
amendment.

Principal amounts owed under the Credit Facility bear interest at LIBOR plus
7.50% or the prime rate plus 5.75%, at the Company's option. In addition to the
cash interest charges outlined above, we are to pay an incremental PIK interest
on the outstanding principal balance of 1.0% from April 15, 2002 though March
31, 2003, increasing to 2.0% from April 1, 2003 through maturity. The
incremental PIK interest is payable upon maturity. We are also to pay a PIK fee
equal to 1.0% of the outstanding principal balance on April 15, 2002, 2.0% on
October 1, 2002, and 3.0% on April 1, 2003. PIK fees are payable upon maturity.

Required principal installments are $0.30 million on July 1, 2002, October 1,
2002, and January 1, 2003, and payments of $7.2 million on April 1, 2003 and
July 1, 2003, with the remaining balance due at maturity on September 30, 2003.
The Credit Facility also has mandatory prepayment provisions for certain asset
sale transactions and excess cash flows, as defined. These prepayment provisions
are applied to future required quarterly installments. Accordingly, $0.21 of the
$0.30 due on October 1, 2002 was paid in July as a result of the disposition of
one dental location in June 2002.

The Credit Facility contains several covenants, including but not limited to,
restrictions on our ability to incur indebtedness or repurchase shares, a
prohibition on dividends without prior approval, prohibition on acquisitions,
and fees for excess earnout and debt payments, as defined. There are also
financial covenant requirements relating to compliance with specified cash flow,
liquidity, and leverage ratios. Our obligations, including all subsidiaries in
the guarantees, under the Credit Facility are secured by a security interest in
the equipment, fixtures, inventory, receivables, subsidiary stock, certain debt
instruments, accounts and general intangibles of each of such entities.

The amendment to the Credit Facility met the criteria of substantial
modification as outlined under the provisions of EITF 96-19. As such, the
amendment met the requirements of an extinguishment of debt. Accordingly, in the
second quarter of 2002 we recorded an extraordinary loss of approximately $2.6
million. The extraordinary loss represents amendment fees of $2.0 million
incurred to extinguish the original note and $0.60 million for the write-off of
the non-amortized portion of deferred financing costs associated with the
original Credit Facility agreement. Professional fees and bank PIK fees paid, or
anticipated to be paid, of $5.9 million for the execution of the amended Credit
Facility have been capitalized and are being amortized over the remaining life
of the Credit Facility. At June 30, 2002 $4.4 million in anticipated future PIK
fees are included in other current liabilities.

         Senior Subordinated Notes

In June 2000, we raised $36.5 million from the sale of debt and equity to Levine
Leichtman Capital Partners II, L.P. ("Levine") under a securities purchase
agreement (the "Securities Purchase Agreement"). The equity portion of the
transaction comprised 458,333 shares of common stock valued at $11.0 million.
The debt portion of the transaction comprised a senior subordinated note with a
face value of $25.5 million (the "Levine Note"). As part of the transaction with
Levine, we also issued a warrant to purchase 354,167 shares of the Company's
common.

In April 2001, we entered into an amendment to the Levine Note that met the
criteria of substantial modification as outlined in EITF 96-19. As such, the
Levine Note was considered extinguished, with a new note issued in its place. In
connection with the amendment, the lender waived the defaults under the Levine
Note that existed at December 31, 2000 due to failure to meet certain financial
ratio covenants and reset all covenants for 2001 and subsequent years, in
addition to certain other modifications. As consideration for the amendment, we
paid an amendment fee of $2.3 million, payable in additional notes, increased
the payment-in-kind ("PIK") interest rate to 16.5% and reduced the price of the
warrants from an initial strike price of $41.04 per share to $20.88 per share.

In April 2002, we entered into an additional amendment to the Levine Note. In
connection with the amendment, the lender reset all covenants for 2002 and
subsequent years, in addition to certain other modifications. As consideration
for the amendment, we agreed to pay an amendment fee of $2.0 million, payable in
additional notes and increase the PIK interest rate by one-half percentage
point. The amendment fee has been capitalized and is being amortized over the
remaining life of the Levine Note.

The entire principal of the Levine Note is due September 2005 but may be paid
earlier at our election, subject to a prepayment penalty. Additionally, the
Levine Note has mandatory principal prepayments based upon a change in
ownership, certain asset sales, or excess cash flows. The Levine Note bears
interest at 12.5%, payable monthly, with an option to pay the interest in a PIK
note. The Company is currently issuing PIK notes at 17.0% for payment of current
interest amounts owed. The Securities Purchase Agreement contains covenants,
including but not limited to, restricting our ability to incur certain
indebtedness, liens or investments, restrictions relating to agreements
affecting capital stock, maintenance of a specified net worth and compliance
with specified financial ratios.

         Convertible Subordinated Notes

In 1998, we issued $30 million of subordinated convertible notes ("Convertible
Notes"). The Convertible Notes mature June 2006 and currently bear interest at
8.0%, payable semi-annually with an option to pay the interest in a PIK note
also bearing interest at 8.0%, which we are currently exercising for payment of
current interest amounts due. In April 2001, we entered into an amendment to the
Convertible Notes and the lender waived the cross-default provision that existed
at December 31, 2000 due to the covenant violations under the Credit Facility
and agreed to reset all covenants for 2001 and subsequent years, in addition to
certain other modifications. As consideration for the amendment, we agreed to
reduce the conversion price of the notes. The Convertible Notes are convertible
into shares of the common stock at $39.00 for each share of common stock
issuable upon conversion of outstanding principal and accrued but unpaid
interest on such subordinated notes and shall be automatically converted into
common stock if the rolling 21-day average closing market price of the common
stock on 20 out of any 30 consecutive trading days is more than $107.40

         Preferred and Common Stock

We are authorized to issue 30,000,000 shares of Preferred Stock. Presently
authorized series of our Preferred Stock include the following series:

o    Series A--100 shares authorized, issued and outstanding;

o    Series B--70,000 shares authorized, zero issued or outstanding;

o    Series C--100 shares authorized, zero shares issued or outstanding; and

o    Series  D--2,000,000  shares  authorized,  1,574,608  shares are issued and
     outstanding.

The Company's presently authorized Preferred Stock rank senior to outstanding
Common Stock. The shares of Series B Preferred Stock were authorized in
connection with issuance of the Convertible Notes as discussed above. The Series
B Preferred Stock conversion provision of the Convertible Notes has expired.
Accordingly, although the Series B Preferred Stock is authorized, the Company
does not expect any such shares to ever be issued. Similarly, 100 shares of
Series C Preferred Stock were authorized and issued in connection with the
Convertible Note issuance, but then converted into 10 shares of common stock in
the March 1999 merger transaction. The Company does not expect any shares of
Series C Preferred Stock to be issued. The shares of Series D Preferred Stock
are convertible into shares of our Common Stock at the rate of one-sixth of a
share of Common Stock for each share of Series D Preferred Stock (assuming there
are no declared but unpaid dividends on the Series D Preferred Stock), in each
case subject to adjustment for stock splits, reverse splits, stock dividends,
reorganizations and similar anti-dilutive provisions. The Series D Preferred
Stock holders are entitled to vote on all matters as to which the Common Stock
shareholders are entitled to vote, based upon the number of shares of Common
Stock the Series D Preferred Stock is convertible into. The Series A Preferred
Stock is not convertible, is entitled to elect a director, and is otherwise
non-voting.

A total of 36,920 and 56,541 outstanding shares of Common Stock issued at a
price of $2.70 and $1.35 per share, respectively, are subject to repurchase by
us at the original issue price at our election.


Dental Location Dispositions


Effective May 31, 2001, we also completed the stock sale of DCA, a wholly-owned
subsidiary, and certain other assets in Maryland, Virginia and Indiana. The
transaction also includes the assets associated with the notes receivable made
to officers of DCA as discussed in the notes to the Consolidated Financial
Statements. Total consideration was $36.0 million, less the assumption of
related debt and operating liabilities. Upon the two-year anniversary of the
transaction close, we shall have the right to repurchase the assets of DCA,
based upon a multiple of EBITDA subject to a minimum price, as defined in the
agreement. In connection with the sale of assets, we entered into a five-year
license agreement for $2.6 million in cash, payable in installments, for use of
our proprietary practice management system, subject to negotiations for
additional term extensions. Such amount is recorded as deferred revenues and
amortized over the life of the agreement. The parties also entered into the
transition services agreement and a business collaboration agreement delineating
the use of the practice management system, the joint purchase of supplies, the
joint negotiation for managed care contracts, training systems, and other
similar operational matters.

During 2002, we disposed of one dental location for proceeds of $0.28 million
and our insurance carrier reimbursed us for $0.32 million on certain
dispositions that occurred in 2001, resulting in a net gain of $0.19 million.
During 2001, we disposed or identified under performing dental locations for
disposition ("Disposed Locations"). In connection with the sale of DCA and
Disposed Locations the Company wrote off $40.2 million in total assets, yielded
proceeds of $21.4 million, net of closing costs and recorded a total loss of
$12.3 million for the year ended December 31, 2001. The total recorded loss
includes $1.7 million for the provision of direct transaction closing costs.


Impairment of long-lived assets

In July 2001, the FASB issued Statement of Financial Accounting Standard No.
142, "Goodwill and Other Intangible Assets" ("SFAS 142"). Under SFAS 142,
goodwill and indefinite lived assets are no longer amortized but are reviewed
annually for impairment. Separate intangible assets that are not deemed to have
an indefinite life will continue to be amortized over their useful lives. The
amortization provisions of SFAS 142 apply to goodwill and intangible assets
acquired after June 30, 2001. With respect to goodwill and intangible assets
acquired prior to June 30, 2001, the provisions of SFAS 142 are effective upon
its adoption effective beginning fiscal year 2002. We are currently performing
the required impairment tests of goodwill and indefinite lived intangible assets
as of January 1, 2002. We have completed the first step of the two-step
transitional impairment analysis required by SFAS 142. This analysis indicated
that the carrying amount of our net assets exceeds the fair value. Preliminary
results of the second step of the transitional impairment analysis indicates
that an impairment charge totaling $50 to $100 million will be required,
although such analysis in not complete. We expect to complete this analysis in
the fourth quarter of 2002.


Item 3.  Quantitative and Qualitative Disclosures About Market Risks

We do not utilize financial instruments for trading purposes and hold no
derivative financial instruments, which could expose us to significant market
risk. Our interest expense is sensitive to changes in the general level of
interest rates as our credit facility has interest rates based upon market LIBOR
or prime rates, as discussed in Note 5 to the condensed consolidated financial
statements. To mitigate the impact of fluctuations in market rates, we purchase
fixed interest rates for periods of up to 180 days on portions of the
outstanding credit facility balance.

At June 30, 2002, we had $81.1 million in floating rate debt under the credit
facility. The detrimental effect on our pre-tax earnings of a hypothetical 100
basis point increase in the interest rate under the credit facility would have
been approximately $0.40 million for the six-months ended June 30, 2002. This
sensitivity analysis does not consider any actions we might take to mitigate our
exposure to such a change in the credit facility rate. The hypothetical change
used in this analysis may be different from what actually occurs in the future.
Our remaining subordinated notes and long-term debt obligations of $90.1 million
are at fixed rates of interest.


<PAGE>




PART II - OTHER INFORMATION


Item 2.  Changes in Securities and Use of Proceeds

The payment of dividends is within the discretion of the Board of Directors;
however, we intend to retain earnings from operations for use in the operation
and expansion of our business and do not expect to pay cash dividends in the
foreseeable future. In addition, our senior credit lender currently prohibits
the payment of cash dividends. Any future decision with respect to dividends
will depend on future earnings, operations, capital requirements and
availability, restrictions in future financing agreements and other business and
financial considerations.

Item 3.  Defaults Upon Senior Securities

As of December 31, 2001, the Company was in default under its existing senior
revolving Credit Facility and Levine Note due to failure to meet certain
financial ratio covenants. In April 2002, we entered into an amendment to our
Credit Facility and Levine Note, which, among other provisions, waived the
defaults that existed at December 31, 2001 and reset all covenants for 2002 and
subsequent years. For further information, see note 5 to the condensed
consolidated financial statements.

Item 5.  Other Information

Nasdaq in a letter dated May 16, 2002, notified the Company that it failed to
comply with the minimum bid price and the minimum market value of publicly held
shares requirements for continued listing set forth in Market Place Rules
4450(b)(3) and 4450(b)(4), and that its securities were, therefore, subject to
delisting from the Nasdaq National Market. In June, the Company was also
notified that it also did not meet the minimum market value of publicly held
shares requirement for transfer to the Nasdaq SmallCap Market and, as a result,
the Company's common stock began trading on the OTC Bulletin Board on June 13,
2002. The Interdent, Inc. common stock symbol was also changed to DENT.OB to
reflect the change in market listings.

First Union National Bank is the Transfer Agent and Registrar for the stock of
InterDent, Inc. Shareholder matters, such as a transfer of shares, stock
transfer requirements, missing stock certificates and changes of address, should
be directed to First Union at the following address and telephone number:

                  First Union National Bank
                  Shareholder Services Group
                  1525 W. WT Harris Blvd., 3C3
                  Charlotte, North Carolina 28288-1153
                  Telephone Numbers: 704/590-0394, or toll-free 800/829-8432


Item 6.  Exhibits, Financial Statement Schedules and Reports on Form 8-K
-------

(a)      Exhibits

3.1      Bylaws of InterDent, Inc., a Delaware Corporation.

99.1     Chief Executive Officer's Certification Pursuant to Section 1350 of
         Chapter 63 of Title 18 of the United States Code.

99.2     Chief Financial Officer's Certification Pursuant to Section 1350 of
         Chapter 63 of Title 18 of the United States Code.


(b)      Reports on Form 8-K

         No reports on Form 8-K were filed in the three months ended June 30,
2002.

<PAGE>





                                   SIGNATURES



In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.



                                               INTERDENT, INC.
                                                (Registrant)


Date:        August 13, 2001           By:       \s\ H. WAYNE POSEY
     ------------------------------         ---------------------------------
                                                  H. Wayne Posey
                                                  Chief Executive Officer


                                       By:       \s\ L. THEODORE VAN EERDEN
                                            --------------------------------
                                                  L. Theodore Van Eerden
                                                  Chief Financial Officer